Lantern Pharma (LTRN) Return on Capital Employed (2021 - 2026)
Lantern Pharma's (LTRN) quarterly Return on Capital Employed came in at 310.34% in Q1 2026, down 19873.0% YoY from N/an in Q1 2025, and down 35.16% on a QoQ basis from 229.62% in Q4 2025.
Lantern Pharma (LTRN) Return on Capital Employed (2021 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 6 years of Return on Capital Employed data on file, last reported at 310.34% in Q1 2026.
- Quarterly Return on Capital Employed fell 19873.0% year-over-year to 310.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 310.34% (down 19873.0% YoY) and the FY2025 annual result came in at 130.26%, down 5688.0% from the prior year.
- Return on Capital Employed slipped to 310.34% in Q1 2026, from 229.62% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.86% in Q1 2022 to a low of 310.34% in Q1 2026.
- A 5-year average of 86.58% and a median of 51.2% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 465 bps — and 2026, when it tumbled 19873 bps.
- Tracing LTRN's Return on Capital Employed over 5 years: stood at 25.01% in 2022, then tumbled by 66 bps to 41.55% in 2023, then tumbled by 127 bps to 94.13% in 2024, then plunged by 144 bps to 229.62% in 2025, then plunged by 35 bps to 310.34% in 2026.
- The last three Return on Capital Employed figures came in at 310.34% (Q1 2026), 229.62% (Q4 2025), and 171.31% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | -310.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -310.34% |
| Dec 31, 2025 | -229.62% |
| Sep 30, 2025 | -171.31% |
| Jun 30, 2025 | -142.63% |
| Mar 31, 2025 | -111.61% |
| Dec 31, 2024 | -94.13% |
| Sep 30, 2024 | -72.25% |
| Jun 30, 2024 | -59.11% |
| Mar 31, 2024 | -51.20% |
| Dec 31, 2023 | -41.55% |
| Sep 30, 2023 | -35.54% |
| Jun 30, 2023 | -30.62% |
| Mar 31, 2023 | -26.95% |
| Dec 31, 2022 | -25.01% |
| Sep 30, 2022 | -23.09% |
| Jun 30, 2022 | -25.97% |
| Mar 31, 2022 | -20.86% |
| Dec 31, 2021 | -16.12% |
| Sep 30, 2021 | -11.71% |